Patents by Inventor Fatih M. Uckun

Fatih M. Uckun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6,7-dimethoxyquinazolines and therapeutic use thereof
    Patent number: 6638939
    Abstract: Quinazoline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: October 28, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Xing-Ping Liu, Rama Krishna Narla
  • Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections
    Publication number: 20030186991
    Abstract: The invention provides compounds which inhibit reverse transcriptase (RT) and which inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The compound of the invention are phenoxyethyl-thiourea-pyridines. The invention additionally provides a method for inhibiting reverse transcriptase activity of a retrovirus, such as HIV-1, comprising contacting the retrovirus with a compound of the invention. The invention additionally provides a method for inhibiting replication of a retrovirus, such as HIV-1, comprising contacting the retrovirus with a compound of the invention.
    Type: Application
    Filed: April 15, 2003
    Publication date: October 2, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Vanadium (IV) metallocene complexes having spermicidal activity
    Patent number: 6627655
    Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, including their corresponding therapeutic compositions are described.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: September 30, 2003
    Assignee: Parker Hughes Institute
    Inventors: Osmond D'Cruz, Phalguni Ghosh, Fatih M. Uckun
  • R-isomers of nonnucleoside inhibitors
    Publication number: 20030181717
    Abstract: Novel chiral derivitaves of non-nucleoside inhibitors (NNI), particularly R-isomers of halopyridyl and thiazoyl thiourea compounds are provided as potent inhibitors of reverse transcriptase (RT), and particularly of retroviral RT, most particularly HIV RT. The stereospecific compounds and compositions of the invention inhibit replication of retrovirus, particularly human immunodeficiency virus-1 (HIV-1) and drug resistant strains.
    Type: Application
    Filed: January 21, 2003
    Publication date: September 25, 2003
    Applicant: Parker Hughes Institute located at Roseville, Minnesota
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Platinum (II) antitumor compounds
    Publication number: 20030176410
    Abstract: The present invention describes platinum (II) compounds and compositions useful for treating a subject with a tumor and/or inducing apoptosis in a population of cells. The present invention also describes pharmaceutical compositions containing the aforementioned inventive compound(s) in combination with a pharmaceutically acceptable carrier. Additionally, the invention further provides a method of inducing apoptosis in a population of cells and a method of treating a subject with a tumor, wherein the method comprises administering to the subject a therapeutically effective amount of the aforementioned compound(s) or composition(s).
    Type: Application
    Filed: May 15, 2002
    Publication date: September 18, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rama K. Narla
  • Cathepsin inhibitors in cancer treatment
    Patent number: 6605589
    Abstract: Embodiments of the present invention provide methods for inhibiting tumor cell growth, or treating cancer cells, in a subject through the administration of a cathepsin inhibitor or inhibitors. Methods for inhibiting inflammatory disease cells as well as other cathepsin expressing cells in a subject with a cathepsin inhibitor or inhibitors are also within the present invention. Furthermore, the present invention relates to inducing cytotoxicity or apoptosis in cells by administering a cytotoxic or an apoptotic dose of a cathepsin inhibitor or inhibitors to the cell. Finally, the present invention relates to the administering of cathepsin expressing vectors to tumor cells so as to inhibit the tumor cells growth.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: August 12, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, De-Min Zhu
  • BTK inhibitors and methods for their identification and use
    Publication number: 20030144351
    Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors, including allergy treatments.
    Type: Application
    Filed: April 2, 2002
    Publication date: July 31, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Ravi Malaviya
  • Method for inhibiting C-jun expression using JAK-3 inhibitors
    Publication number: 20030144178
    Abstract: The invention provides a method for inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with a substance that inhibits the activity of Janus family kinase 3 (JAK-3). The invention also provides a therapeutic method for preventing or treating a pathological condition in a mammal wherein c-jun activation is implicated and inhibition of its activation is desired comprising administering to a mammal in need of such therapy, an effective amount of a substance that inhibits the activity of JAK-3. Novel compounds that are JAK-3 inhibitors, as well as pharmaceutical compositions comprising the compounds are also provided.
    Type: Application
    Filed: April 19, 2001
    Publication date: July 31, 2003
    Applicant: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Estrogens for treating ALS
    Patent number: 6592845
    Abstract: A method for preventing and treating ALS by administering a phytoestrogen, preferably genistein.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: July 15, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Vuoung N. Trieu, Xing-Ping Liu
  • Inhibiting collagen-induced platelet aggregation
    Patent number: 6589992
    Abstract: The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering to the subject a pharmaceutically effective amount of a compound or composition that inhibits BTK and collagen-induced platelet aggregation. The condition of platelet aggregation includes cardiovascular, hematopoietic and cerebrovascular diseases.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 8, 2003
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Phorboxazole derivatives for treating cancer
    Publication number: 20030125366
    Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.
    Type: Application
    Filed: May 14, 2002
    Publication date: July 3, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rama K. Narla, Craig Forsyth, Chi Sing Lee, Feryan Ahmed, Russel Drew Cink
  • Cyclohexenyl-ethyl-thiourea compounds and use
    Publication number: 20030125331
    Abstract: Novel CycloHexenyl-Ethyl-Thiourea (CHET) compounds as inhibitors of reverse transcriptase and effective agents for the treatment of HIV infection, including mutant, drug-sensitive, drug-resistant, and multi-drug resistant strains of HIV.
    Type: Application
    Filed: October 22, 2002
    Publication date: July 3, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Ventatachalam
  • Phenethyl-thiourea compounds and use
    Patent number: 6586450
    Abstract: Novel phenylethyl-thiourea (PHET) compounds as inhibitors of reverse transcriptase and effective agents for the treatment of HIV infection, including mutant, drug-sensitive, drug-resistant, and multi-drug resistant strains of HIV.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: July 1, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Ventatachalam
  • Gel-microemulsion formulations
    Publication number: 20030083314
    Abstract: A pharmaceutical composition adapted for use as a spermicide, the composition comprising a gel-microemulsion comprising an oil-in-water microemulsion and a polymeric hydrogel. The gel-microemulsion can be used in a spermicidal method.
    Type: Application
    Filed: September 19, 2001
    Publication date: May 1, 2003
    Inventors: Seang Yiv, Mingshu Li, Osmond D'Cruz, Fatih M. Uckun
  • Quinazolines for treating brain tumor
    Patent number: 6552027
    Abstract: Novel substituted quinozaline compounds and conjugates useful to inhibit the growth of brain tumor cells and to inhibit adhesion and migration of brain tumor cells. The compounds of the invention include 4-(3′-bromo-4′-hydroxy phenyl)-amino-6,7-dimethoxyquinazoline and this compound covalently bound to EGF.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: April 22, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rama Krishna Narla, Xing-Ping Liu
  • Vanadium compounds for treating cancer
    Publication number: 20030073678
    Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.
    Type: Application
    Filed: May 8, 2002
    Publication date: April 17, 2003
    Applicant: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Yanhong Dong, Phalguni Gosh
  • R-isomers of nonnucleoside inhibitors
    Patent number: 6545152
    Abstract: Novel chiral derivitaves of non-nucleoside inhibitors (NNI), particularly R-isomers of halopyridyl and thiazoyl thiourea compounds are provided as potent inhibitors of reverse transcriptase (RT), and particularly of retroviral RT, most particularly HIV RT. The stereospecific compounds and compositions of the invention inhibit replication of retrovirus, particularly human immunodeficiency virus-1 (HIV-1) and drug resistant strains.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: April 8, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Taracad K. Venkatachalam
  • Aryl phosphate derivatives of d4T having anti-HIV activity
    Patent number: 6537975
    Abstract: Aryl phosphate derivatives of d4T with para-bromo substitution on the aryl group show markedly increased potency as anti-HIV agents without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. In a preferred aspect of the present invention, the phosphorus of the aryl phosphate group is further substituted with an amino acid residue that may be esterified or substituted, such as a methoxy alaninyl group.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: March 25, 2003
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Rakesh Vig
  • Ikaros isoforms and mutants
    Patent number: 6537766
    Abstract: Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematoloic malignancy, are also provided.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: March 25, 2003
    Assignee: Hughes Institute
    Inventors: Fatih M. Uckun, Mya L. Crotty
  • Cytotoxic compounds
    Publication number: 20030055100
    Abstract: Compounds are described that bind to tubulin causing tubulin depolymerization and inhibiting tubulin polymerization. The compounds of the invention are therapeutically effective to inhibit cellular proliferation, for example, as effective anti-cancer agents. The compounds can also induce cytotoxicity in cells such as leukemia cells. The chemical structure of the compounds includes a furan, thiophene, thiazole, oxazole, or imidazole group at one end of the molecule (head) and a hydrophobic, aliphatic chain at the other end of the molecule (tail).
    Type: Application
    Filed: April 18, 2002
    Publication date: March 20, 2003
    Inventors: Fatih M. Uckun, Shyi-Tai M. Jan